Zypadhera: new depot injection for schizophrenia

Lilly has launched a prolonged-release olanzapine injection, Zypadhera.

The injection is available in three different strengths, 210mg, 300mg and 405mg, and is licensed for use in the maintenance treatment of adult patients with schizophrenia sufficiently stabilised during acute treatment with oral olanzapine.

Zypadhera should be administered only by deep intramuscular gluteal injection by a healthcare professional trained in the appropriate injection technique and in locations where post-injection observation and access to appropriate medical care in the case of overdose can be assured.

View Zypadhera drug record

Further information: Lilly

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

New antibiotic guidance for leg ulcer infection

New antibiotic guidance for leg ulcer infection

NICE has issued guidance on antibiotic choices and...

New insertion site for Nexplanon following safety concerns

New insertion site for Nexplanon following safety concerns

The MHRA has amended its advice relating to the long-acting...

Antibiotic Treatments in Adults, Summary of Regimens

Antibiotic Treatments in Adults, Summary of Regimens

Dose regimens for common bacterial infections.